Anemia Clinical Trial
— TRANSFORMOfficial title:
TRANSFORM - Observational Cohort Study of Aranesp Use in EU Haemodialysis Patients Switched From Mircera
To describe the time course of hemoglobin concentration in EU hemodialysis patients switched from methoxy polyethylene glycol-epoetin beta (PEG epoetin beta; Mircera) to darbepoetin alfa (Aranesp).
Status | Completed |
Enrollment | 1027 |
Est. completion date | July 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients >18 years of age. CKD diagnosis, receiving hemodialysis - Received PEG epoetin beta for 14weeks prior to switching to darbepoetin alfa and received at least one dose of darbepoetin alfa. |
Observational Model: Cohort
Country | Name | City | State |
---|---|---|---|
Belgium | Research Site | Edegem | |
France | Research Site | Antony | |
France | Research Site | Aurillac | |
France | Research Site | Béziers | |
France | Research Site | Blois | |
France | Research Site | Boulogne sur Mer | |
France | Research Site | Cahors | |
France | Research Site | Essey lès Nancy | |
France | Research Site | Grabels | |
France | Research Site | La Réunion | |
France | Research Site | La Roche sur Yon Cedex 9 | |
France | Research Site | Libourne | |
France | Research Site | Lille Cedex | |
France | Research Site | Metz | |
France | Research Site | Paris | |
France | Research Site | Paris | |
France | Research Site | Poitiers | |
France | Research Site | Saint Nazaire | |
France | Research Site | Saint Pierre | |
France | Research Site | Saint Priest en Jarez | |
France | Research Site | Saint-Denis de la Réunion | |
France | Research Site | Strasbourg | |
France | Research Site | Vandoeuvre Les Nancy Cedex | |
Germany | Research Site | Kiel | |
Germany | Research Site | Nordhorn | |
Greece | Research Site | Athens | |
Greece | Research Site | Athens | |
Netherlands | Research Site | Arnhem | |
Spain | Research Site | Ribeira | Galicia |
Spain | Research Site | Santiago de Compostela | Galicia |
Spain | Research Site | Santiago de Compostela | Galicia |
Switzerland | Research Site | Sion |
Lead Sponsor | Collaborator |
---|---|
Amgen |
Belgium, France, Germany, Greece, Netherlands, Spain, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hemoglobin Concentration at Monthly Intervals | Hemoglobin concentration from 3 months prior to switch to darbepoetin alfa until the end of the observation period. | Month -3, -2, -1 (pre-switch), and Month 1, 2, 3, 4, 5 and 6 (post-switch) | No |
Secondary | PEG Epoetin Beta Dose From the Start of the Observation Period Until the Switch | Mean weekly doses were calculated per participant by first calculating a mean daily dose for the interval (by dividing each dose evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose. Weekly doses >150 µg have been excluded as they were deemed infeasible values derived by the algorithm. | Month -3, Month -2, Month -1 | No |
Secondary | Darbepoetin Alfa Dose From the Switch Date Until the End of the Observation Period | Mean weekly doses were calculated per participant by first calculating a mean daily dose for the interval (by dividing each dose evenly between the days bounded by its date of administration and the day before the next dose, then taking a mean of these partial doses for the days in the interval) and multiplying by 7 to convert to a weekly dose. Weekly doses >150 µg have been excluded as they were deemed infeasible values derived by the algorithm. | Month 1, 2, 3, 4, 5 and 6 | No |
Secondary | Dose Ratio Measured at the Time of Switch From PEG Epoetin Beta to Darbepoetin Alfa | Dose ratio is the average weekly dose of the first darbepoetin alfa dose divided by the average weekly dose of peg-epoetin beta at switch (µg darbepoetin alfa per 1 µg pegylated-epoetin beta). | Week -1 and Week 1 | No |
Secondary | Hemoglobin Concentration Rate of Change by Period | The hemoglobin rate of change is the maximum monthly increase and maximum monthly decrease for the pre- and post-switch periods. Within each period, the difference was calculated between each hemoglobin value and the most recent hemoglobin value taken at least 28 days previously. The rate of change was calculated by dividing this difference by the number of days in the interval and multiplying by 28. The maximum and minimum rate of change was then determined per participant. | Thre months prior to switch and 6 months after the switch | No |
Secondary | Percentage of Participants With Hemoglobin Excursions | The percentage of participants with at least one hemoglobin excursion, defined as hemoglobin concentrations below 10.0 g/dL and above 12.0 g/dL during the pre- and post-switch periods. | Month -3, -2, -1, 1, 2, 3, 4, 5 and 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |